Protective effect of sulglycotide on human gastric mucosa exposed to taurocholic acid.
Sulglycotide is a non-systemic drug used in the treatment of peptic ulcer. It seems also to possess cytoprotective action. A double-blind cross-over study on the influence of oral sulglycotide on gastric mucosal cell loss induced by taurocholic acid (20 mM + HCl 7mM in 100 ml normal saline) was carried out in sixteen healthy volunteers by means of the DNA-loss technique. Each subject received either sulglycotide (400 mg thrice daily) or a placebo in random order on the basis of a double-blind cross-over design. Sulglycotide appeared to reduce the gastric cell loss induced by taurocholic acid. These results can explain the therapeutic effect of sulglycotide in peptic disease.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D004247:DNA / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000032:analysis / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012795:Sialoglycoproteins / Q000494:pharmacology*; D013656:Taurocholic Acid / Q000037:antagonists & inhibitors*
D000897:Anti-Ulcer Agents; D012795:Sialoglycoproteins; C009354:sulglicotide; D013656:Taurocholic Acid; D004247:DNA